Cotreatment of DOXO with CUR reduced p65NF-κB translocation to the nucleus, inhibited NF-κB-p300 cross-talk, triggering p53-p300 interaction, and consequently activated p53-dependent apoptosis in DOXO-resistant breast cancer models [74]. Here, EP300 is linked to breast cancer.